Direct oral anticoagulants (DOACs) and parenteral direct
Eikelboom JW, Weitz JI. New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. BMJ 2011; 342:c7270. Altena R, van Roon E, Folkeringa R, et al. Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring. Haematologica 2014; 99:e26. Siegal DM, Konkle BA.
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts. 1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie,
Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions. Since the first approval in 2010, DOACs have emerged a
Direct Oral Anticoagulants: A Quick Guide - Expert Review - ISCP
Direct Oral Anticoagulants: A Quick Guide. Reviewer: Julia Sikorska, James Uprichard. Date: December 6, 2018. For more than 50 years, oral vitamin K antagonists (VKAs) were the choice of anticoagulant for the long-term treatment and prevention of arterial and venous thromboembolic events (VTE). VKA treatment is safe and effective, if a high
Peripheral Matters | Dose-Reduced Direct Oral Anticoagulants: Practical
Direct oral anticoagulants (DOACs) are commonly used for the prevention of thrombosis in several cardiovascular contexts, including stroke prevention in patients with atrial fibrillation (AFib) and primary prevention, acute treatment or extended-duration secondary prevention of venous thromboembolism (VTE). 1,2
- What are direct oral anticoagulants?
- Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions. Since the first approval in 2010, DOACs have emerged a …
- What are direct oral anticoagulants (DOACs)?
- 3 Center for Preventive Cardiology Knight Cardiovascular Institute Oregon Health & Science University Portland OR. Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist.
- Why do clinicians need a DOAC?
- With the expanding role of DOACs, clinicians are faced with increasingly complex decisions relating to appropriate agent, duration of treatment, and use in special populations. This review will provide an overview of DOACs and act as a practical reference for clinicians to optimize DOAC use among common challenging scenarios.
- How does adherence to DOACs affect anticoagulation?
- tive feedback regarding DOAC adherence. Given the short half-lives of the DOACs, patients who frequently miss DOAC doses may not derive similar protective b nefit as medication-compliant patients. Conversely, the rapid onset of the DOACs does ensure therapeutic anticoagulation as soon as the DOAC dose is taken, theoretically minimizing the w
- Does rapid onset of a DOAC reduce the risk of subtherapeutic anticoagulation?
- nefit as medication-compliant patients. Conversely, the rapid onset of the DOACs does ensure therapeutic anticoagulation as soon as the DOAC dose is taken, theoretically minimizing the w ndow of subtherapeutic anticoagulation. These considerations should be weighed with the potential risk
- Are direct oral anticoagulants a good alternative to vitamin K antagonist?
- ABSTRACT: Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long- standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular con-ditions.
